NSE: CIPLA · 30 September 2026 · Dated market coverage
- The stock is -2.41% at ₹1,346.00.
- Likely reason:Sector-wide pharma weakness and mild profit-taking
- Approximate traded value is₹141.96 crore.
- It is -19.55% from its 52-week high and +15.47% from its 52-week low.
- The stock is being compared withNifty Pharmaalongside the Nifty 50.
Why Is CIPLA Share Price Falling 2.41% Today?
Latest NSE EOD report: 2026-09-29. Today’s Volume: 1,054,654; 5-Day Avg. Volume: 1,200,361; 20-Day Avg. Volume: 955,339; Volume vs 20-Day Avg.: 1.10x; Delivery Quantity: 924,048; Delivery %: 62.46%; Number of Trades: 44,697.
CIPLA shares declined 2.41% today, settling at ₹1,346.0 after trading near the day’s low of ₹1,346.0 and hitting a high of ₹1,383.1. Trading volume stood at approximately 10.55 lakh shares, which is relatively subdued at 0.88 times its 5-day average volume, reflecting moderate participation during the session.
The stock underperformed both the broader benchmark and its sectoral peers. The Nifty index fell 0.42%, while the Nifty Pharma sector index recorded a sharper drop of 1.84%, indicating broader weakness across pharmaceutical counters that weighed on Cipla’s price action.
While no single confirmed corporate catalyst triggered today’s decline, the stock has been consolidating following recent developments, including an exclusive partnership with Qilu Pharmaceutical for a biosimilar to Keytruda in the US and ongoing preparations for its upcoming quarterly financial results scheduled for late October.
low confidence
- Nifty Pharma sector index dropped 1.84%
- Volume remained below the 20-day average at 0.88x of 5d volume
- No fresh adverse corporate disclosures reported
Ownership & Transaction Activity
WittyTrades Data Insight
Price Position:The stock is near the lower end of the day’s trading range.
Move From Open:-2.68%.
Intraday Range:2.69% of the previous close.
5-Day Performance:-2.68%; 20-Day Performance:-4.73%.
Latest Company Developments
What Should Traders and Investors Watch Next?
- Upcoming Q2 financial results scheduled for October 27, 2026
- Updates on US FDA inspections at manufacturing facilities including InvaGen and Pithampur
- Progress on the Qilu Pharmaceutical biosimilar partnership and US pipeline execution
- Sectoral trends in the Nifty Pharma index and institutional delivery volumes
Catalyst note:No single confirmed corporate trigger caused today’s move; the decline reflects broader sector pressure.
Frequently Asked Questions
What is the likely reason for today’s move?
Cipla’s downward move aligns with broader weakness across pharmaceutical equities, with the Nifty Pharma sector falling sharply during the session. In the absence of negative company-specific announcements today, the price action appears driven by sectoral headwinds and routine technical selling.
Is trading volume elevated?
Today’s volume is 1,054,654. The latest 20-day average available is 955,339, equivalent to about 1.10x of the recent average.
Before acting on this stock
Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review theWittyTrades subscription plans and research segments.
Article by:WittyTrades Research Desk